Lebanon, New Hampshire 03756

  • ERCP Acute Pancreatitis


The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.


Inclusion Criteria: 1. Scheduled for an ERCP at Dartmouth-Hitchcock 2. Age greater than 18 years old 3. Ability to provide written informed consent Exclusion Criteria: 1. Inability to provide written informed consent 2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis 3. Current ongoing acute pancreatitis 4. Previously documented allergy to NSAID 5. Contra-indication to NSAID therapy (creatinine level >1.4 or active peptic ulcer disease), already taking NSAIDs (other than aspirin therapy for cardioprotection) 6. Pregnant or nursing mothers



Primary Contact:

Principal Investigator
John M Levenick, MD
Dartmouth-Hitchcock Medical Center

Backup Contact:


Location Contact:

Lebanon, New Hampshire 03756
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.